Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference
07 mai 2020 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...
Esperion Reports First Quarter 2020 Financial Results and Provides Company Update
06 mai 2020 16h05 HE
|
Esperion Therapeutics, Inc.
Company Secures Marketing Approvals for NEXLETOL™ and NEXLIZET™ Tablets in the U.S. as well as for NILEMDO™ and NUSTENDI™ Tablets in EuropeNEXLETOL™ (bempedoic acid) Tablets Commercially Available in...
Esperion to Report First Quarter 2020 Financial Results May 6, 2020
30 avr. 2020 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 30, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2020 financial results after the close of the U.S. financial markets on May...
Esperion to Participate in Fireside Chat at the 19th Annual Needham Virtual Healthcare Conference
09 avr. 2020 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 09, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...
Esperion Announces European Commission Approval of the NUSTENDI™ (bempedoic acid and ezetimibe) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
06 avr. 2020 07h05 HE
|
Esperion Therapeutics, Inc.
– First Non-Statin, LDL-C Lowering Combination Medicine Ever Approved in Europe – – NUSTENDI Is Approved for Patients Who Require Additional LDL-Cholesterol Lowering on a Background Statin, Other...
Esperion Announces European Commission Approval of the NILEMDO™ (bempedoic acid) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
06 avr. 2020 07h00 HE
|
Esperion Therapeutics, Inc.
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in Europe in Almost Two Decades for Indicated Patients – – NILEMDO Is Approved for Patients Who Require Additional...
Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare
30 mars 2020 16h15 HE
|
Esperion Therapeutics, Inc.
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine in the U.S. in Nearly 20 Years for Indicated Patients Awaiting a New Option –– Esperion Aims to Set New Industry Standard by...
Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC)
28 mars 2020 09h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2...
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC)
23 mars 2020 07h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 23, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2...
Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors
18 mars 2020 07h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 18, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of...